Skip to main content

blindness Archives

Novel methods to treat glaucoma

Nov. 8, 2018—Increasing a certain signaling molecule prevents the degeneration of retinal cells that are lost in glaucoma, suggesting a new way to treat this disease.

Read more


Aqueous humor, microRNAs and glaucoma

Apr. 10, 2018—New findings highlight microRNAs — molecules that regulate gene expression — that are differentially expressed in glaucoma and could be candidate biomarkers or targets for therapy.

Read more


Imaging probe for retinal disease

Oct. 12, 2016—An imaging probe developed at Vanderbilt detects retinal inflammation early and may allow therapeutic intervention to prevent blindness.

Read more


Building intestinal brush borders

Feb. 8, 2016—Studies of the molecular complex that helps build specialized cellular surfaces could shed light on the mechanisms underlying a genetic deaf-blindness syndrome accompanied by intestinal disease.

Read more


New targets for diabetic retinopathy

Jan. 21, 2016—Certain protein factors have been identified as attractive targets for treating diabetic retinopathy, a major cause of blindness in adults.

Read more


In a zebrafish’s eye

Jul. 29, 2015—Vanderbilt investigators demonstrate that a certain eye lens protein is evolutionarily conserved between zebrafish and rat, suggesting that zebrafish can be used as a model system to understand eye lens disorders such as cataracts.

Read more


Biomarker for diabetic eye disease

Sep. 26, 2014—A person’s mitochondrial gene “signature” could predict risk for diabetic retinopathy and guide early intervention strategies.

Read more


Keeping an eye on blast trauma

Aug. 19, 2014—Understanding the cellular and molecular responses of the eye to blast injury could guide new treatment development.

Read more


Shining a light on night blindness

Oct. 24, 2013—Vanderbilt researchers are studying how mutations in the receptor for light, rhodopsin, cause light blindness.

Read more


Metabolic profiling of vision loss

Sep. 27, 2013—A panel of metabolites – small molecules that are part of metabolic processes – that are unique to macular degeneration will shed light on the disease and aid diagnosis.

Read more


‘Bionic eye’ new option for retinitis pigmentosa patients

Jul. 25, 2013—Vanderbilt University Medical Center has been chosen as one of 12 sites in the United States to offer the first FDA-approved bionic eye for the treatment of retinitis pigmentosa (RP).

Read more


Insights on glaucoma gene mutations

Jun. 26, 2013—Glaucoma-causing mutations in the gene for myocilin reduce secretion of the protein into the aqueous humor, suggesting a new option for treatment.

Read more


Page 1 of 212

Recent Stories from VUMC News and Communications Publications

Our amazing skin

Vanderbilt Medicine

Our amazing skin

Biology and the beat

Vanderbilt Medicine

Biology and the beat

Community care

Vanderbilt Nurse

Community care

Survive and thrive

Hope

Survive and thrive

more